Chronic Kidney Failure Clinical Trial
— BELASBRIDGEOfficial title:
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
NCT number | NCT05562869 |
Other study ID # | RC21_0587 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 3, 2024 |
Est. completion date | May 3, 2027 |
Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to prevent rejection. Currently the main limitation of kidney transplantation is the occurrence of chronic graft dysfunction due to the CNI nephrotoxicity. Thus, strategies to minimize or stop CNI have been developed as belatacept, a fusion protein (CTLA4-Ig) blocking the ligand of the main CD28 costimulatory molecule. In the original phase III trial, used de novo in combination with MMF (without CNI) belatacept allowed to obtain a better renal function as soon as 1 year and a better graft and patient survival after 7 years. Despite these excellent results, belatacept has not become the gold standard due to a higher incidence of early rejection. In addition, belatacept is not covered by the french social security policy, because benefits are considered insufficient with respect to the cost. Patients with poor early graft function are a preferred indication of belatacept. It is then used instead of CNI at 3 months post-transplant allowing to improve kidney function without over-risk of rejection. Currently after conversion, belatacept is maintained indefinitely due to the supposed CNI chronic nephrotoxicity. However this one is more and more questionable. Thus, the investigators assume that in patients with poor function at 3 months posttransplantation the belatacept's benefit could be obtained by a transient replacement of CNI by belatacept from 3 to 12 months post-transplantation. It is the feasibility of this strategy and its medico-economic impact that the investigators wish to study.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | May 3, 2027 |
Est. primary completion date | May 3, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - adult older than 18 years old. - transplantation of a deceased or living donor kidney (non-human leukocyte antigen(HLA)-identical) with blood type (ABO) compatibility - no contraindication to the protocol graft biopsy (10 weeks post transplant) - treatment by CNI / MPA +/- prednisone - renal function estimated by creatinine clearance according to CKD-EPI <30 ml / min / 1.73m2. - having no difficulty in understanding and communicating with the investigator and his representatives. - Agreeing to give informed written consent - benefiting from a Social Security policy. - results of the 10-week post-transplant renal biopsy finding no rejection or BK virus (member of the polyomavirus family) nephropathy, no recurrence, no thrombotic microangiopathy, no cortical necrosis. - Seropositivity for Epstein-Barr virus (EBV) - negative pregnancy test and agreement on the use of effective contraception throughout the study Exclusion Criteria: - Presence of Donor Specific Antibody during kidney transplant or appeared at 3 months post-transplantation. - seropositivity for HIV - another history of other solid organ transplants (outside the kidney) - primary non-function (persistence of a need for dialysis at 3 months post-transplantation) - participation in progress to another interventional clinical study - any clinical condition that the investigator considers incompatible with the course of the study. - contraindication to belatacept and Tacrolimus - Pregnant or breastfeeding woman - Inability of the patient to comply with study procedures - Person placed under guardianship or curatorship, under safeguard of justice |
Country | Name | City | State |
---|---|---|---|
France | CHU Nantes | Nantes | Loire Atlantique |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, Longuet H, Sberro-Soussan R, Doucet L, Grall A, Legendre C. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria — View Citation
Vincenti F. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jun 30;374(26):2600-1. doi: 10.1056/NEJMc1602859. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of a transient replacement of CNIs by belatacept in renal transplant patients with early graft dysfunction. Creatinine clearance did not decrease by more than 25% from the cessation of belatacept 6 months after reintroduction of CNI. | Feasibility was defined by preserved renal function and good tolerance 6 months after reintroduction of CNI.
Renal function was defined as preserved if creatinine clearance (according to Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI)) did not decrease by more than 25% from the cessation of belatacept. The good tolerance of CNI was defined by the absence of complications leading to the cessation of treatment. |
Month 15 | |
Secondary | Evaluate the effectiveness of belatacept treatment on renal function (creatinine clairance) and to prevent rejection. (Number of rejection épisodes) | Longitudinal monitoring of renal function (Day 0, Month 3, Month 6, Month 9) and collection of rejection episodes. | Day 0, Month 3, Month 6, Month 9 | |
Secondary | Evaluate the tolerance of treatments (belatacept during phase 1 and CNI during phase 2). Number of adverse events. | Collection of infectious episodes and neoplasias | Month 3, Month 6, Month 9, Month 12, Month 15 | |
Secondary | Estimate the cost of care (from 3 months to 18 months post-transplant) and compare with the cost of a theoretical arm benefiting from belatacept continuously and a theoretical arm benefiting from CNIs continuously. | Number of care resources used for treatment : number of medication, number of hospitalization, number of transportation, number of consultations, number of medical procedures, possible home help and associated costs over 15 months of follow-up, and collection of cost data in the literature for the comparison. | Month 3, Month 6, Month 9, Month 12, Month 15 | |
Secondary | Evaluate the evolution of the quality of life during the 15 months of follow-up and compare it to a theoretical arm benefiting from belatacept continuously, and a theoretical arm benefiting from CNIs continuously: generic EuroQol-5D scale | Measurement of quality of life scores (generic EuroQol-5D scale) every 3 months for 15 months and collection of quality of life data in the literature for comparison. | Month 3, Month 6, Month 9, Month 12, Month 15 | |
Secondary | Evaluate the differential impact of SNFs and belatacept on cell populations of the immune system | Differential analysis of cell populations by standardised flow cytometry combined with unbiased analysis. | Month 3, Month 6, Month 9, Month 12, Month 15 | |
Secondary | Evaluate the differential impact of NICs and belatacept on the level of CMV replication and its clinical consequences. | Longitudinal monitoring of CMV PCR | Month 3, Month 6, Month 9, Month 12, Month 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT00781690 -
Reduction of Heparin Dose in Dialysis With Evodial System
|
N/A | |
Completed |
NCT00806130 -
Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
|
||
Completed |
NCT00153621 -
Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients
|
N/A | |
Completed |
NCT06165211 -
Nature-Based Sound Application For Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT04013620 -
CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
|
Phase 3 | |
Withdrawn |
NCT03998917 -
Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
|
||
Completed |
NCT02586376 -
Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF)
|
N/A | |
Completed |
NCT00794326 -
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
|
Phase 3 | |
Completed |
NCT05185999 -
Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients
|
Phase 1 | |
Completed |
NCT03076528 -
An Innovative Virtually Supervised Exercise for Dialysis Patients
|
Phase 2 | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Completed |
NCT00804453 -
Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line
|
N/A | |
Unknown status |
NCT00788905 -
Comparison of Conventional Dialysis and the Allient System
|
N/A | |
Completed |
NCT01085552 -
Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects
|
Phase 1 | |
Completed |
NCT00694824 -
Vascular Calcification's Risk Factors in Haemodialysis Patients
|
||
Completed |
NCT00074620 -
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
|
Phase 2 | |
Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
Completed |
NCT03437538 -
Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
|
N/A | |
Completed |
NCT01450670 -
Observational Study of Kibow Biotics in Dialysis Patients
|